These findings suggest that HDAC inhibition—including the novel small molecule CAY10603—sensitizes GBM to temozolomide and confers potent anti-tumor effects that combat GBM (e.g., reducing proliferation, EMT, stemness). This evidence concerns the gene HDAC9 and glioblastoma.